Details of the Drug

General Information of Drug (ID: DMO091F)

Drug Name
Balsalazide
Synonyms
Balsalazida; Balsalazido; Balsalazidum; Colazal; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Balsalazide (INN); Balsalazide [INN:BAN]; Colazal (TN); Colazide (TN); (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
Indication
Disease Entry ICD 11 Status REF
Inflammatory bowel disease DD72 Approved [1]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 357.32
Topological Polar Surface Area (xlogp) 2.2
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 269.85861 micromolar/kg/day [2]
Chemical Identifiers
Formula
C17H15N3O6
IUPAC Name
5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
Canonical SMILES
C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
InChI
InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
InChIKey
IPOKCKJONYRRHP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
54585
ChEBI ID
CHEBI:267413
CAS Number
80573-04-2
DrugBank ID
DB01014
TTD ID
D0A6KR
ACDINA ID
D00058

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Inflammatory bowel disease
ICD Disease Classification DD72
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 3.97E-03 0.16 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Balsalazide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Balsalazide caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [13]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Balsalazide and Glibenclamide. Acute diabete complication [5A2Y] [14]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Balsalazide and Glipizide. Acute diabete complication [5A2Y] [14]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Balsalazide and Inotersen. Amyloidosis [5D00] [15]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Kanamycin. Bacterial infection [1A00-1C4Z] [16]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Streptomycin. Bacterial infection [1A00-1C4Z] [16]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Etidronic acid. Bone paget disease [FB85] [17]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Balsalazide and Iodipamide. Cholelithiasis [DC11] [18]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Methoxyflurane. Corneal disease [9A76-9A78] [16]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [16]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [16]
Moxetumomab pasudotox DMN63DZ Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [16]
Mercaptopurine DMTM2IK Moderate Decreased metabolism of Balsalazide caused by Mercaptopurine mediated inhibition of non-CYP450 enzyme. Mature B-cell lymphoma [2A85] [19]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Balsalazide and Exjade. Mineral absorption/transport disorder [5C64] [20]
Gallium nitrate DMF9O6B Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Gallium nitrate. Mineral excesses [5B91] [16]
Temsirolimus DMS104F Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Temsirolimus. Renal cell carcinoma [2C90] [16]
Colistimethate DMZ9BMU Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Colistimethate. Respiratory infection [CA07-CA4Z] [16]
Salsalate DM13P4C Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Salsalate. Rheumatoid arthritis [FA20] [16]
Telavancin DM58VQX Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [16]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Balsalazide and Tolbutamide. Type 2 diabetes mellitus [5A11] [14]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Balsalazide and Plazomicin. Urinary tract infection [GC08] [16]
⏷ Show the Full List of 21 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Eisenoxyd E00585 56841934 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Balsalazide 750 mg capsule 750 mg Oral Capsule Oral
Balsalazide 1100 mg tablet 1100 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077806.
2 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
3 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
4 The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
5 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
8 Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
11 Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
12 Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
15 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
17 Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
18 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
19 Lewis LD, Benin A, Szumlanski CL, et al. "Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction." Clin Pharmacol Ther 62 (1997): 464-75. [PMID: 9357398]
20 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.